Microparticles, Vector of Genetic Information During HIV Infection

Assistance Publique Hopitaux De Marseille15 enrolled

Overview

The aim of the investigators study is to demonstrate in healthy subjects and a cohort of patients infected with HIV, the presence of miRNAs in circulating peripheral blood microparticles (MPs).

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

HIV,

Interventions

Blood samplesBIOLOGICAL

Eligibility

Sex: MALEMin age: 30 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age of 40 +/-10 years * Seronegativity for the HIV 2 * Patients of the group A: seropositivity for the HIV 1 confirmed in ELISA and Western Blot for at least 2 years and having never received from antiretroviral treatment, with a viral plasmatique load \> 1000 copies / ml * Patients of the group B: seropositivity for the HIV 1 confirmed in ELISA and Western Blot for at least 2 years and under stable antiretroviral treatment for at least 6 months, with a viral load undetectable plasmatique (\< 40 copies / ml) * patients of the group C : Matching on the age (+/-3 years) to a patient * Be considered healthy by the Investigator after a clinical examination Seronegativity for the HIV 1 confirmed in ELISA the day of the taking Exclusion Criteria: group A et B * Age of \< 30 years and \> in 50 years * Seropositivity for the HIV 2 group C Seropositivity for the HIV 2 \- Be under medicinal treatment

Locations (1)

Assistance Publique Hopitaux de Marseille

Marseille, France

Outcomes

Primary Outcomes

NUMBER OF miRNAs

Time frame: 2 YEARS

Secondary Outcomes

Demonstrate the presence of miRNAs in microparticles

Time frame: 2 YEARS

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.